Addressing Multidrug-Resistant Bacteria: A Comparison of Antibiotic Assessments
Author Information
Author(s): Rémy Dumont, Etienne Lengliné, Clara Delorme, Jean-Pierre Bru, Sévérine Ansart, Elisabeth Aslangul, Sophie Kelley, Pierre Cochat, Sylvie Chevret, Thierno Diatta
Primary Institution: Haute Autorité de Santé, Saint-Denis, France
Hypothesis
Transparency on the regulatory appraisals of antibiotics would provide an incentive to pharmaceutical development.
Conclusion
The study shows consistent reimbursement decisions for antibiotics against multidrug-resistant bacteria across different European health technology assessment bodies.
Supporting Evidence
- TC-HAS recognized a clinical benefit for all evaluated indications.
- Five antibiotics were recommended for restricted use to protect against resistance emergence.
- Comparative analysis showed consistent reimbursement decisions across HTA bodies.
Takeaway
This study looks at how different countries decide which new antibiotics to approve and pay for, especially those that fight superbugs.
Methodology
A qualitative analysis of the Transparency Committee of the French National Authority for Health opinions regarding antibiotics assessment between 2016 and 2020 was performed.
Potential Biases
The decisions of HTA bodies may be influenced by the positions of other HTA bodies due to the public availability of opinions.
Limitations
The analysis period was limited to 2016-2020, with only 12 different antibiotics evaluated.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website